Department of Pathology Microbiology and Immunology

Receptor’s role in stopping H. pylori

The immune receptor NOD1 may be a prime target for preventing or treating H. pylori infections — the most significant risk factor for stomach cancer, Vanderbilt researchers have discovered.

Low oxygen and antibody responses

Mark Boothby and colleagues are exploring the factors that contribute to antibody production and quality, which are key to our defense against pathogens and response to vaccines.

Keeping bone in its place

Jonathan Schoenecker and colleagues have discovered a new mechanism for the formation of bone in soft tissues — a complication of severe injuries that causes pain and limits mobility.

bacteria microbiome

How bugs overcome host defenses

Vanderbilt researchers led by Eric Skaar are probing the mechanisms bacteria use when faced with nutrient starvation — a host defense strategy called “nutritional immunity.”

Lab manager Rachel Nargi prepares a B-cell culture during the recent “sprint” to develop an antibody-based treatment for Zika virus infection.

VUMC-led team ‘sprints’ to develop Zika virus treatment

In January scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis were given an audacious goal to develop — in 90 days — a protective antibody-based treatment that potentially will stop the spread of the Zika virus.

Cancer prevention drug also disables H. pylori bacterium

A medicine currently being tested as a chemoprevention agent for multiple types of cancer has more than one trick in its bag when it comes to preventing stomach cancer, Vanderbilt researchers have discovered.

1 14 15 16 17 18 32